Results 111 to 120 of about 17,823 (170)

Clinical Evidence for Topotecan-Paclitaxel Non–Cross-Resistance in Ovarian Cancer

, 2001
Purpose: A large, randomized study comparing the efficacy and safety of topotecan versus paclitaxel in patients with relapsed epithelial ovarian cancer showed that these two compounds have similar activity. In this study, a number of patients crossed
Phillipe Vennin, Wim ten Bokkel Huinink, Martin Gore, Robert Coleman, J. Carmichael, Marek Spaczynski, Giorgio Bolis, H. Malmström, Graham Ross, M. Spaczynski, J. Malfetano, P. Vennin, S. Z. Fields, J. F. Héron, John Malfetano, M. Gore, A. Gordon, C. Scarabelli, W. ten Bokkel Huinink, Henric Malmström, Claudio Scarabelli, Neville Davidson, N. Davidson, G. Bolis, Jean-François Héron, R. Coleman, G. Ross, James Carmichael, Scott Z. Fields, Alan Gordon   +29 more
core   +1 more source

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

, 1997
PURPOSE Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen.
M Spanczynski, M Gore, J F Heron, I Hudson, J Malfetano, C Scarabelli, W ten Bokkel Huinink, H Malmström, C Broom, A Gordon, R Coleman, G Bolis, J Carmichael, N Davidson, S C Fields   +14 more
core   +1 more source

Mathematical models characterising the kinetics and dynamics of topotecan to account for drug resistance mechanisms [PDF]

This thesis describes the use of mathematical modelling in studying the kinetics and dynamics of the anti-cancer agent topotecan (TPT), a semi-synthetic derivative of the natural extract camptothecin (CPT), which has been found to act as an inhibitor ...
Atari, M. I. (Mohammed Isam)
core  

PP2A Activation as a Senotherapeutic in Neuroblastoma. [PDF]

Cancers (Basel)
Nazam N, Shirley SN, Opara JC, Manzoor S, Shaikh MG, Brown ML, Nande P, Eakes AM, Kaimari A, Leavenworth JW, Ohlmeyer M, Beierle EA.   +11 more
europepmc   +1 more source

Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan. [PDF]

Front Immunol
Wang J, Jiang H, Niu J, Liu L, Wu Y, Shi J, Liu L, Yin S, Feng C, Zhang L, Yang M, Yi Z.   +11 more
europepmc   +1 more source

Artificial Intelligence-Guided Prioritization and Experimental Evaluation of Synergistic Target Combinations for Breast Cancer Therapy. [PDF]

Pharmaceuticals (Basel)
Feng C, Feng Q, She S, Yang R, Li M, Gong L, Rui M.   +6 more
europepmc   +1 more source

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. [PDF]

Exp Hematol Oncol
Chiappa M, Villa V, Sias F, Grasselli C, Sala L, Canesi S, Marabese M, Mason S, Dibitetto D, Fruscio R, Damia G.   +10 more
europepmc   +1 more source

Pars Plana Vitrectomy for Retinal Detachment or Vitreous Haemorrhage after Retinoblastoma Regression: A 20-Year Single-Centre Experience. [PDF]

Ocul Oncol Pathol
Rajan RP, V M, Kim U, Kannan NB, Ramasamy K, Sharma A.   +5 more
europepmc   +1 more source

Multi-Omics Identification of UBE2C as a Prognostic Biomarker and Therapeutic Target Linked to Topotecan Sensitivity in Cervical Cancer. [PDF]

Oncol Res
Raj EN, Li CJ, Cheng SH, Yong SB, Wen ZH, Chiang AJ.   +5 more
europepmc   +1 more source

Intra-arterial chemotherapy for retinoblastoma: a structured narrative review. [PDF]

World J Pediatr Surg
Ren YH, Kang D, Shi C, Sun W.
europepmc   +1 more source